Effects of the HMG-CoA reductase inhibitor-Pravastatin sodium (Mevalotin) on plasma lipid abnormalities in patients with chronic renal failure under hemodialysis.

1991 ◽  
Vol 24 (10) ◽  
pp. 1385-1390
Author(s):  
Tadahiro Nishi ◽  
Rie Kurita ◽  
Sachio Taguchi ◽  
Nobuyuki Watanabe ◽  
Makoto Kinoshita ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Reductase Inhibitor ◽  
Plasma Lipid ◽  
Hmg Coa Reductase ◽  
Pravastatin Sodium ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase ◽  
Lipid Abnormalities

Protective Effects of Rosuvastatin in Experimental Renal Failure Rats via Improved Endothelial Function

2012 ◽  
Vol 15 (3) ◽  
pp. 356-364 ◽  
Author(s):  
Yong-zhen Liu ◽  
Min Liu ◽  
Yi-ming Zhang ◽  
Li Kang ◽  
Ping-zhi Chen ◽  
...  
Keyword(s):  
Renal Failure ◽  
Renal Function ◽  
Endothelial Dysfunction ◽  
Inflammatory Cytokine ◽  
Reductase Inhibitor ◽  
Interstitial Fibrosis ◽  
Cytokine Expression ◽  
Hmg Coa Reductase ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

Rosuvastatin is a statin (3-hydroxy-3-methylglutaryl coenzyme-A [HMG-CoA] reductase inhibitor) that also serves as an endothelial dysfunction salvager in many disease models. Endothelial dysfunction is assumed to play a pivotal role in the process of chronic renal failure. The authors tested rosuvastatin on a rat model of renal failure with hypertension. Renal failure was induced by 5/6 nephrectomy (Nx). Fisher rats were divided into four groups: sham ( n = 10), sham + rosuvastatin ( n = 10), Nx ( n = 9), and Nx + rosuvastatin ( n =10). After 4 weeks, the authors determined renal function, lipid profile, and urine albumin excretion, investigated small renal arteries for endothelium function in response to acetylcholine by perfused juxtamedullary nephron technique, and detected intrarenal inflammatory cytokine expression by real-time reverse transcription polymerase chain reaction. 5/6 Nx significantly increased blood urea nitrogen, serum creatinine, and systolic/diastolic blood pressure, and severe albuminuria developed. The deterioration of renal function, hypertension, and albuminuria were almost normalized by rosuvastatin therapy; in addition, rosuvastatin prevented intrarenal inflammatory cytokine expression and the impaired response to acetylcholine of the renal endothelium. Microscopically, rosuvastatin significantly inhibited the development of progressing renal fibrosis, preserved glomerular structure and tubular integrity, and significantly reduced the degree of tubular atrophy and interstitial fibrosis. In conclusion, HMG-CoA reductase inhibitor rosuvastatin can ameliorate markers of endothelium dysfunction and offers a significant protective effect against the development of renal failure caused by 5/6 Nx in rats. Rosuvastatin might, therefore, represent a novel therapeutic agent for chronic kidney disease.

Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells

2004 ◽  
Author(s):  
Takemi Otsuki ◽  
Haruko Sakaguchi ◽  
Tamayo Hatayama ◽  
Tomohiro Fujii ◽  
Takayuki Tsujioka ◽  
...  
Keyword(s):  
Reductase Inhibitor ◽  
Hmg Coa Reductase ◽  
Myeloma Cells ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase ◽  
Human Myeloma Cells

HMG-COA REDUCTASE INHIBITOR AFFECTS BLOOD PRESSURE AND VASCULAR REACTIVITY

1995 ◽  
Vol 22 (s1) ◽  
pp. S316-S317 ◽  
Author(s):  
N. Li ◽  
M. Sawamura ◽  
Y. Nara ◽  
K. Kizawa ◽  
K. Ikeda ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Reductase Inhibitor ◽  
Vascular Reactivity ◽  
Hmg Coa Reductase ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase
Sign in / Sign up

Export Citation Format

Share Document